752 related articles for article (PubMed ID: 32145872)
21. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Kariyawasam HH
Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
[No Abstract] [Full Text] [Related]
22. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
Lelegren MJ; Son SY; Han JK; Lam KK
Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
[TBL] [Abstract][Full Text] [Related]
23. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
24. Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
Eschenbacher W; Straesser M; Knoeddler A; Li RC; Borish L
Immunol Allergy Clin North Am; 2020 Nov; 40(4):539-547. PubMed ID: 33012318
[TBL] [Abstract][Full Text] [Related]
25. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
26. The role of biologics in chronic rhinosinusitis: a systematic review.
Iqbal IZ; Kao SS; Ooi EH
Int Forum Allergy Rhinol; 2020 Feb; 10(2):165-174. PubMed ID: 31869863
[TBL] [Abstract][Full Text] [Related]
27. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
[TBL] [Abstract][Full Text] [Related]
28. Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy.
Kariyawasam HH; James LK
Drug Des Devel Ther; 2020; 14():5483-5494. PubMed ID: 33328726
[TBL] [Abstract][Full Text] [Related]
29. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
Favier V; Daveau C; Carsuzaa F; Fieux M; Vandersteen C; Castillo L; Papon JF; de Gabory L; Saroul N; Verillaud B; Rumeau C; Jankowski R; Michel J; de Bonnecaze G; Lecanu JB; Coste A; Béquignon E; Malard O; Mortuaire G
BMJ Open; 2024 May; 14(5):e083112. PubMed ID: 38749694
[TBL] [Abstract][Full Text] [Related]
30. Innovative treatments for severe uncontrolled chronic rhinosinusitis with nasal polyps.
Huang Y; Zhang N; Bachert C
Expert Rev Clin Immunol; 2023; 19(8):837-845. PubMed ID: 37083285
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
32. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
[TBL] [Abstract][Full Text] [Related]
33. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review.
Aldajani A; Alroqi A; Alromaih S; Aloulah MO; Alsaleh S
Am J Otolaryngol; 2022; 43(6):103615. PubMed ID: 36057193
[TBL] [Abstract][Full Text] [Related]
34. A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyposis.
Brown WC; Senior B
Curr Allergy Asthma Rep; 2020 Apr; 20(6):16. PubMed ID: 32323067
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody therapy in sinonasal disease.
Chiarella SE; Sy H; Peters AT
Am J Rhinol Allergy; 2017 Mar; 31(2):93-95. PubMed ID: 28281440
[TBL] [Abstract][Full Text] [Related]
37. [The perspectives of biologics in the treatment of chronic rhinosinusitis with nasal polyps].
Zhang L
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Nov; 37(11):853-855. PubMed ID: 37905479
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
39. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
Rivero A; Liang J
Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
[TBL] [Abstract][Full Text] [Related]
40. Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP).
Scadding GK; Scadding GW
J Allergy Clin Immunol; 2022 Mar; 149(3):895-897. PubMed ID: 34752829
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
